Title: Over-the-counter Analgesics in Pregnancy and Offspring Neonatal Outcomes: A Retrospective Cohort Study

Authors: [1]Aikaterini ZAFEIRI, MSci, Ms, [2]Edwin A. RAJA, PhD, [3]Rod T. MITCHELL, MBChB, PhD, [4]David C. HAY, PhD, [5]Sohinee BHATTACHARYA, MBBS, PhD, [1]Paul A. FOWLER, FRSB, PhD

[1]Institute of Medical Sciences, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, United Kingdom, [2]Medical Statistics Team, Institute of Applied Health Sciences, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, United Kingdom, [3]MRC Centre for Reproductive Health, The Queen's Medical Research Institute, University of Edinburgh,47 Little France Crescent, Edinburgh, EH16 4JT, UK, [4]MRC Centre for Regenerative Medicine, 5 Little France Drive, Edinburgh, UK, [5]Aberdeen Centre for Women's Health Research, Institute of Applied Health Sciences, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, United Kingdom,

Corresponding Author: Aikaterini Zafeiri, Institute of Medical Sciences, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, United Kingdom, cell phone number: (+44)7713837285, email: r01az17@abdn.ac.uk

Running Title: Maternal over-the-counter analgesia and offspring outcomes

Abstract

Objective To identify associations between *in utero* exposure to 5 over-the-counter (OTC) analgesics and adverse neonatal outcomes.

Design Retrospective cohort study

Setting Aberdeen UK

Population 151,141 singleton deliveries, 1985 to 2015

Methods Self-reported, non-prescription, consumption of paracetamol, aspirin, ibuprofen, diclofenac and naproxen during pregnancy and neonatal outcomes were obtained from the Aberdeen Maternity and Neonatal Databank (AMND). Univariable and multivariable regression analyses were performed to investigate associations between analgesic use and offspring neonatal outcomes. Crude (cORs) and adjusted odds ratios (aORs) with 95% confidence intervals (CIs) were reported, indicating the strength of association.

Main Outcome Measures Premature delivery (<37 weeks), stillbirth, neonatal death, birthweight, standardised birthweight score, neonatal unit admission, APGAR score at 1 and 5 minutes, cryptorchidism, neural tube and amniotic band defects, hypospadias and gastroschisis.

Results Pregnancies exposed to at least one of the 5 analgesics were significantly independently associated with increased odds for premature delivery <37 weeks (aOR=1.50, 95%CI 1.43-1.58), stillbirth (aOR=1.33, 95%CI 1.15-1.54), neonatal death (aOR=1.56, 95%CI 1.27-1.93), birthweight <2500g (aOR=1.28, 95%CI 1.20-1.37), birthweight >4000g (aOR=1.09, 95%CI 1.05-1.13), admission to neonatal unit (aOR=1.57, 95%CI 1.51-1.64), APGAR score <7 at 1 minute (aOR=1.18, 95%CI

1.13-1.23) and 5 minutes (aOR=1.48, 95%CI 1.35-1.62), neural tube defects (aOR=1.64, 95%CI 1.08-2.47) and hypospadias (aOR=1.27, 95%CI 1.05-1.54 males only).

Conclusions There was a high prevalence of OTC analgesics use during pregnancy, which steeply increased during the 30-year study period. Analgesic consumption was independently associated with multiple adverse neonatal offspring outcomes. The use of paracetamol in combination with other NSAIDs conferred the highest risk.

Funding Biotechnology and Biological Sciences Research council (BBSRC) funding under the EASTBIO doctoral training programme.

Key words acetaminophen, aspirin, diclofenac, ibuprofen, *in utero* exposure, naproxen, offspring outcomes, over-the-counter analgesics, offspring outcomes, paracetamol, pregnancy

Introduction

Globally 23-85% of women use one or more types of prescribed medications during pregnancy [1,2]. However, an equally high proportion of expectant mothers self-medicate using non-prescription medicines [3,4]. Studies assessing the prevalence of non-prescription analgesic use during pregnancy report an increase, especially in Western countries [5]. However, due to their abundance, it is not always feasible to determine exact consumption rates and dosage. Furthermore, the mechanisms of action for most of these compounds is not fully understood even though most OTC analgesics can diffuse through the placenta and reach the developing fetus [6]. Combined with the altered maternal pharmacokinetics during pregnancy, and the limited pregnancy safety data for these compounds, significant health concerns regarding human exposure and safe use during pregnancy are raised [7].

Some analgesics are considered safe to consume during pregnancy, while use of non-steroidal anti-inflammatory drugs (NSAIDs) is discouraged beyond gestational week 30. Current evidence is conflicting regarding their safety, raising important public health concerns. Several studies have reported increased risks for multiple adverse outcomes including hypospadias, cryptorchidism, amniotic band defects and neural tube defects [8–12], whilst others have not found significant associations [13–18]. However, the use of small cohorts makes it difficult to draw firm conclusions and definite recommendations[13,18–20]. With several study design, methodology and/or result generalisability limitations, more data in larger populations globally are needed to make more informed decisions, which will impact on current practice. Here we report on the prevalence of maternal consumption of five different OTC analgesics during pregnancy and their associations with offspring neonatal outcomes using a

large cohort of pregnancies spanning three decades of data from a single maternity hospital serving a whole population in the North East of Scotland.

Materials and Methods

This retrospective cohort study utilised data collected in the Aberdeen Maternity and Neonatal Databank (AMND) in Aberdeen, UK on 151,141 pregnancies over a 30 year period (1985-2015). Details about AMND have been previously published [21]. Data were collected continuously from medical notes of women from their first antenatal visit and every visit after that. Data were then entered by dedicated coding staff into a computerised database. Data validity was ensured via checking completeness of data entry against NHS (UK National Health Service) returns monthly and constant data cleaning and validation against case notes reported quarterly by the Data Management team to the AMND Steering Committee. A research protocol was submitted and approved by the AMND Steering Committee before data extraction. Approval was received on 6 June 2018. The dataset was fully anonymised, therefore there was no requirement for NHS ethics committee approval.

The main analysis considered consumption during pregnancy of at least one out of five different analgesics: paracetamol (no; yes), ibuprofen (no; yes), naproxen (no; yes), diclofenac (no; yes) or aspirin (no; yes) as the exposure group against no analgesic consumption as the unexposed group. Then, three sub-group analyses against the control group were performed using only paracetamol, only diclofenac, or at least one analgesic from aspirin/naproxen/ibuprofen as exposure groups, excluding pregnancies exposed to multiple analgesics at the same time. As 98.3% of pregnancies using diclofenac were between 2005 and 2015, diclofenac sub-group analysis only considered pregnancies during that time frame in order to rule out any temporal effect. Analgesic consumption data were available for all pregnancy trimesters, however exact timing was not specified in the database.

The offspring outcomes compared between control and exposed groups were: gestation at delivery (preterm <37 gestation weeks, term ≥37 gestation weeks), pregnancy outcome (livebirth, stillbirth, neonatal death), baby weight (low birth weight (LBW) ≤2,499g, high birth weight (HBW) ≥4,000g, normal birth weight (NBW) 2,500g-3,999g), standardised birthweight score was considered as a continuous variable as previously described by Campbell and colleagues (Campbell *et al.*, 1993), baby admission to neonatal unit (no; yes), APGAR score at one and five minutes (<7, ≥7), cryptorchidism (no; yes) (ICD-10 code Q53), neural tube defects (no; yes) (ICD-10 code Q00-07), amniotic band defects (no; yes) (ICD-10 codes Q70-74), hypospadias (no; yes) (ICD-10 code Q54), gastroschisis (no; yes) (ICD-10 code Q79.3). A composite outcome (presence of at least one congenital anomaly (no; yes)) was created using the variables cryptorchidism, neural tube defects, amniotic band defects, hypospadias and gastroschisis.

The baseline characteristics compared between exposed and unexposed pregnancies were (reference category first): year of delivery (1985-1994, 1995-2004, 2005-2015), maternal age at delivery (20-25, <20, 26-35, >35 years), previous pregnancy (no; yes), maternal body mass index (BMI) (normal weight 18.5-24.9 kg/m^2, underweight <18.5 kg/m^2, overweight 25-29.9 kg/m^2, obese <30 kg/m^2), maternal first antenatal visit (1st, 2nd, 3rd trimester), maternal smoking status (non-smoker, smoker, ex-smoker), Scottish Index of Multiple Deprivation (SIMD) decile (1-6, 7-10, decreasing deprivation with increasing score), maternal hypertensive disorders (no disorder, gestational hypertension, preeclampsia, eclampsia), maternal antepartum haemorrhage (no haemorrhage, abruption, placental previa), type of labour (spontaneous, elective caesarean section, induced), type of delivery (spontaneous vaginal delivery, instrumental, caesarean section), analgesia during

labour (no; yes), baby presentation at delivery (occiput anterior, occiput posterior), baby sex (female; male).

Statistical Analysis

Baseline characteristics were compared between exposed and unexposed pregnancies to any analgesic using χ^2 test for categorical variables and t-test for normally distributed continuous variables as appropriate. Relationships between exposures and outcomes were examined by binary logistic regression for binary outcome variables, multinomial logistic regression for nominal categorical outcome variables, and multiple linear regression for continuous variables. The strength of association was reported as odds ratios (ORs) with 95% confidence intervals (CI). The socio-demographic characteristics that were likely to confound our exposure-to-outcome path were identified using a directed acyclic graph (DAG) (Figure S1)[23]. Factors that were associated with consumption of OTC analgesics during pregnancy at 10% level of significance and deemed clinically relevant, were included in the model as confounders. All outcomes were adjusted for year of delivery, maternal age at delivery, SIMD and maternal first antenatal visit. In addition to these confounders, individual outcomes were adjusted for relevant cofactors. Gestation at delivery and pregnancy outcome were both additionally adjusted for maternal hypertensive disorders and antepartum haemorrhage. Weight of the baby, neonatal unit admission, cryptorchidism, neural tube defects, amniotic band defects, hypospadias and gastroschisis variables were also adjusted for gestation at delivery. APGAR score at one and five minutes were adjusted for type of delivery. A p-value of less than 0.05 was considered statistically significant. All statistical analyses were carried

out using IBM SPSS Statistics version 25.0 (Released 2017. IBM SPSS Statistics for Windows, Armonk, NY: IBM Corp.). R version 3.6.2 was used to generate Figure 2.

Results

Overall, from the total 151,141 pregnancies across 30 years, no OTC analgesic consumption was reported in 107,143 (70.9%) pregnancies. At least one OTC analgesic was consumed in 43,998 (29.1%) pregnancies, whereas paracetamol use alone was reported in 24,099 (18.4%) pregnancies. Diclofenac use was observed in 10,473 (8.9%) pregnancies and at least one out of three analgesics (naproxen, ibuprofen, aspirin) was consumed in 762 (0.7%) pregnancies (Figure 1).

Prevalence of use for all five analgesics increased dramatically over the 30-year study period (1985-2015) (Figure 2). Percentage of pregnancies with consumption of at least one analgesic increased from 1.8% in 1985 to 70.6% in 2015. Paracetamol was consumed in 1.3% of pregnancies in 1985 and it continuously increased reaching 42.2% in 2015. Naproxen, ibuprofen or aspirin consumption during pregnancy was less prevalent (Figure 2A), however it also increased during the 30-year study period, starting at 0.5% in 1985 and reaching 1.9% in 2015 (Figure 2B). Diclofenac was consumed in very few pregnancies between 1985 (<0.01%) and 2005 (0.2%). Percentage of consumption, however, dramatically increased during the next decade, reaching 25.0% in just a year (2006) and 45.6% of all pregnancies in 2015.

Table 1 compares the baseline characteristics between the unexposed group of pregnancies where no analgesic was consumed and each of the exposure groups. In most, but not all, comparisons across all four analyses, there was a statistically significant difference ($p<0.001$) for most variables. In the paracetamol sub-group analysis, baby presentation at delivery ($p=0.525$) and sex of the baby ($p=0.861$) were not significantly different between the groups. In the analysis considering

consumption of at least one analgesic from aspirin/naproxen/ibuprofen, again the variables for baby presentation at delivery (p=0.093) and sex of the baby (p=0.732), together with maternal smoking status (p=0.132) and maternal antepartum haemorrhage (p=0.434) were not statistically different compared to the unexposed group. All variables were statistically different between unexposed and exposed groups for the main analysis and diclofenac sub-group analysis.

Table 2 summarises the comparison of neonatal outcomes between the unexposed group (no analgesic at all) and the exposed groups of at least one analgesic, only paracetamol and at least one out of aspirin/naproxen/ibuprofen. Comparison of outcomes for the diclofenac sub-group analysis is shown in Table 3.

All analgesics and neonatal outcomes

As shown in Table 2, compared to unexposed pregnancies in which women did not use any analgesic, pregnancies with consumption of at least one analgesic (paracetamol, diclofenac, aspirin, naproxen, ibuprofen) were independently associated with significantly higher odds for premature delivery (aOR=1.50, 95%CI 1.43-1.58), stillbirth (aOR=1.33, 95%CI1.15-1.54), LBW (aOR=1.28, 95%CI 1.20-1.37), HBW (aOR=1.09, 95%CI 1.05-1.13), baby admission to neonatal unit (aOR=1.57, 95%CI 1.51-1.64), APGAR score <7 at five minutes (aOR=1.48, 95%CI 1.35-1.62), neural tube defects (aOR=1.64, 95%CI 1.08-2.47) and hypospadias (aOR=1.27, 95%CI 1.05-1.54) in adjusted analyses. Significantly decreased odds for APGAR score <7 at one minute were found in the crude analysis (cOR=0.96, 95%CI 0.92-0.99), however when adjusted for year of delivery, maternal age at delivery, SIMD, first gestational booking and type of delivery, the significance changed direction showing significantly increased odds (aOR=1.18, 95%CI 1.13-1.23). A

significantly lower standardised birthweight score (aOR=0.046. 95%CI 0.032-0.059) was found for the exposure group compared to no analgesic at all. Cryptorchidism (aOR=0.92, 95%CI 0.77-1.11), amniotic band defects (aOR=1.02, 95%CI 0.71-1.47), gastroschisis (aOR=1.10, 95%CI 0.56-2.20) and the composite outcome variable (aOR=1.12, 95%CI 0.99-1.26), were all associated with increased odds in the exposure group compared to not exposed, however the association was not significant in the adjusted model. There was no significant association between neonatal death and exposure to at least one analgesic in the crude analysis (cOR=1.19, 95%CI 0.99-1.42), however there were significantly higher odds of neonatal death in the adjusted analysis (aOR=1.56, 95%CI 1.27-1.93) in the exposed group compared to control.

Paracetamol and neonatal outcomes

In the sub-group analysis considering only paracetamol consumption during pregnancy as our exposure group, most of the associations reported in the main analysis remained significant with the same direction of significance (Table 2). The differences were: maternal paracetamol consumption during pregnancy was associated with significantly decreased odds for offspring HBW (cOR=0.94, 95%CI 0.90-0.99) in the crude analysis however significance was lost in the adjusted model (aOR=0.98, 95%CI 0.93-1.02), and there were no significant associations in the adjusted models for neural tube defects (aOR=1.21, 95%CI 0.71-2.06) and hypospadias (aOR=1.07, 95%CI 0.84-1.37).

Aspirin/naproxen/ibuprofen and neonatal outcomes

Consumption of at least one analgesic from aspirin, naproxen or ibuprofen during pregnancy was compared against the same control group of pregnancies where no analgesic was used (Table 2). Again, when comparing associations between groups in this sub-group analysis and main analysis, fewer outcome variants showed similar significance pattern. The only shared significant associations were for increased odds for premature delivery (aOR=1.42, 95%CI 1.08-1.86), stillbirth (aOR=2.34, 95%CI 1.29-4.25) and baby admission to neonatal unit (aOR=1.54, 95%CI 1.22-1.94) in the adjusted regression analyses.

Diclofenac and neonatal outcomes

In the sub-group analysis of pregnancies only exposed to diclofenac, years 2005-2015 were considered, and outcomes were again compared between the diclofenac group and no analgesic consumption group (Table 3). Compared to the main analysis, diclofenac consumption during pregnancy was not significantly associated with premature delivery (aOR=1.10, 95%CI 0.99-1.22), neonatal death (aOR=1.26, 95%CI 0.73-2.15) and APGAR score <7 in one minute (aOR=0.93, 95%CI 0.83-1.04) in the adjusted models. Associations with APGAR score <7 in five minutes (aOR=0.94, 95%CI 0.72-1.23), cryptorchidism (aOR=1.05, 95%CI 0.78-1.42), amniotic band defects (aOR=0.81, 95%CI 0.41-1.58) and gastroschisis (aOR=2.93, 95%CI 0.97-8.88) were no longer significant in both crude and adjusted analyses. Maternal consumption of diclofenac was independently associated with a significant decrease in stillbirth (aOR=0.59, 95%CI 0.41-0.87). It is also interesting to note that diclofenac was the only sub-group analysis agreeing with the main analysis (exposure to at least one analgesic) on the significance of exposure association with

increased incidence of neural tube defects (aOR=3.62, 95%CI 1.95-6.74) and hypospadias (aOR=1.49, 95%CI 1.09-2.03) compared to unexposed pregnancies in adjusted models.

Discussion

Main Findings

There was a dramatic increase in the frequency of OTC (non-prescription) analgesic use in pregnancies between 1985 and 2015. Diclofenac use increased steeply from 2005 (Figure 2A), which reflects the change in Scottish legislation making diclofenac available without prescription in that year. Consumption of paracetamol, ibuprofen, aspirin and naproxen during pregnancy, either in combination or separately, was significantly associated with increased premature delivery, stillbirth, neonatal death, LBW, abnormal standardised birthweight score and more frequent admission to neonatal unit. Consumption of paracetamol alone was further associated with higher odds for APGAR score <7 at one and five minutes both in crude and adjusted analyses.

Surprisingly, exposure to diclofenac only was associated with significant decrease of stillbirth incidence both in crude and adjusted models. Another striking difference of diclofenac with the rest of the analyses was its association with a significant increase of neural tube defects and hypospadias. The reason for such deviation of diclofenac results with the other analgesics might be an underlying maternal condition and/or other compounds used in combination (e.g. prescriptions) by women taking diclofenac. It is possible that the drug could act directly on fetal development then this difference could also be due to structural and/or mechanistic differences of the compound compared to the other drugs, but further studies are required to assess this. Overall, comparing our main analysis with all three sub-analyses, it is evident that the most significant differences were observed when paracetamol was taken with at least one other analgesic. This is mostly due to the high number of

pregnancies where paracetamol was used, comprising almost 55% of the exposed cases in the main analysis.

Strengths and Limitations

A major strength of the present study is the large cohort of 151,141 pregnancies over a 30-year study period from 1985 until 2015, using a robust data source AMND. The dataset contains high quality and consistent data from the geographically defined area of Aberdeen and surrounding district, in the North East of Scotland, UK. In addition, as Aberdeen Maternity Hospital is the only maternity hospital serving the area, over 95% of pregnancies in the area are included in the dataset, minimizing the risk for selection bias. We were able to analyse maternal consumption data of the five most commonly used analgesics available OTC in the UK and most countries. The nature of our data allowed for the analysis of analgesics consumed alone or in combination, better reflecting real-life consumption patterns [43,44]. We were able to adjust for important confounding factors, relevant to each analysed outcome. Adjustment for maternal deprivation also allowed us to further account for potential unmeasured factors that can influence maternal and neonatal health, which is a major strength of our analysis compared to most studies.

A potential concern was that women were probably using analgesics to treat some inherent medical condition which in turn could have been the mediating factor for adverse outcomes. However, since these medications are widely available without prescription, this is unlikely to be a factor that affects the findings of this study.

This study presents results on multiple neonatal outcomes for the given cohort, offering a comprehensive approach to the exploration of associations with *in utero*

analgesic exposure than only focusing on a single outcome of interest. Our data were based on medical notes; however OTC consumption is self-reported, and details on the timing, dosage, product type (single-ingredient vs combination) and administration type were not available in the database. Complete case analyses were performed ignoring pregnancies with missing data in the covariates, however due to the low number of missing data there is little chance that this might have affected the validity of our results. Compared to our cohort size, there were overall very few cases of cryptorchidism, neural tube defects, amniotic band defects, hypospadias and gastroschisis, resulting in potentially underpowered statistical analyses to detect a difference for these outcomes. Our study only considered neonatal health outcomes and follow-up of the offspring was not available at this time.

Interpretation

Previous literature has considered fewer outcomes with fewer analgesic combinations compared to our study. Consistent with our results, increased risk of preterm birth and miscarriage has been associated with analgesic consumption during pregnancy [24–27], while others reported no associations with miscarriage, stillbirth or preterm delivery [20,24,25,28]. Similarly, increased risk for offspring cryptorchidism, hypospadias, neural tube defects, amniotic band defects and gastroschisis have been shown by many studies [8,9,36,10,29–35], although, again, a lack of associations with major birth defects have been reported [14–18,37,38]. Compared to our analysis, all these studies used a smaller cohort, considered a shorter study time and there was frequent disagreement with respect to the choices of adjusted

confounding factors. Another difference is that maternal questionnaires/interviews were frequently the method of choice to evaluate maternal consumption. Some of the studies reported increased risks for specific pregnancy trimesters which is something our study could not evaluate. Differences in study design and adjustment for different confounders might also account for the disagreement of our results that provide a more accurate assessment. Our study is one of the largest in terms of cohort size, duration, number of analgesics and range of outcomes included which might also contribute to differences compared to other studies.

The literature currently reports conflicting evidence, limiting our ability for definite decision-making. OTC analgesics are recommended to women by healthcare professionals in order to deal with pregnancy symptoms and other conditions. Policy-makers have taken a stand on the topic, either being reassuring about OTC use during pregnancy or recommending caution when consumption is necessary [39–42]. Different compounds can affect the mother and the fetus in a different way, and their combined use might worsen the risk for offspring ill health. This study demonstrates the need for additional research, before the field can be confidently directed towards one direction or the other.

Whether the associations we report result from flu, fever, rheumatological or inflammatory conditions, and/or combination with other prescribed medications or solely related to OTC analgesics consumption is a matter of further research. Underlying health conditions could well influence the outcomes we see in this study, however, as these could be very different conditions it is biologically unlikely that they are responsible for the effects we observe here. Our study demonstrates an association of maternal OTC analgesic consumption during pregnancy with adverse neonatal offspring outcomes. Future collaborative approaches such as an individual

patient data meta-analysis that includes follow-up data on long-term outcomes during childhood and adulthood would significantly inform decision making. Going forward, uncovering the mechanisms of action and off target effects will also provide a solid foundation for the development of pregnancy-safe compounds.

Conclusions

Pain control is currently a therapeutic priority during pregnancy. Our results highlight that data on adverse health outcomes for the offspring are crucial to inform guidelines and policies for the management of pain during pregnancy using OTC analgesics that are available without prescription, which is safe for both the mother and the fetus.

Acknowledgements: N/A

Disclosure of interests: Professor David Hay is a founder, director and shareholder in Stemnovate Limited. The remaining authors have no interests to disclose.

Contribution to Authorship: AZ, SB and PAF contributed to the conception, design and coordination of the research. EAR provided critical input in the design and planning of statistical analysis. AZ conducted the statistical analysis and prepared the manuscript, figures and tables. AZ, SB, PAF, RTM and DCH substantially contributed to the analysis and interpretation of the work. All authors contributed to critical discussion of intellectual content, development and review/approval of the final manuscript version.

Funding: This work is supported by the Biotechnology and Biological Sciences Research council (BBSRC) funding the lead author under the EASTBIO doctoral training programme. RTM is supported by UKRI Future Leaders Fellowship (MR/S017151/1). The MRC Centre for Reproductive Health is supported by MRC Centre Grant (MR/N022556/1). The funders had no role in study design, data collection, data analysis, decision to publish, or manuscript preparation.

Ethics Statement: The AMND dataset used in this study was fully anonymised, therefore there was no requirement for ethical approval. The North of Scotland Research Ethics Service has devolved Caldicott approval to the Chair of the AMND steering committee. Approval to access and analyse data was obtained from the AMND steering Committee (AMND 004/2018).

References

1. Gendron M-P, Martin B, Oraichi D, Berard A. Health care providers' requests to Teratogen Information Services on medication use during pregnancy and lactation. *Eur J Clin Pharmacol*. 2009;65(5):523-531.

2. Mitchell AA, Gilboa SM, Werler MM, Kelley KE, Louik C, Hernández-Díaz S. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. *Am J Obstet Gynecol*. 2011;205(1):51.e1-51.e8.

3. Werler MM, Mitchell AA, Hernandez-Diaz S, Honein MA. Use of over-the-counter medications during pregnancy. *Am J Obstet Gynecol*. 2005;193(3):771-777.

4. Glover DD, Amonkar M, Rybeck BF, Tracy TS. Prescription, over-the-counter, and herbal medicine use in a rural, obstetric population. *Am J Obstet Gynecol*. 2003;188(4):1039-1045.

5. Lupattelli A, Spigset O, Twigg MJ, et al. Medication use in pregnancy: A cross-sectional, multinational web-based study. *BMJ Open*. 2014;4(2).

6. Nitsche JF, Patil AS, Langman LJ, et al. Transplacental Passage of Acetaminophen in Term Pregnancy. *Am J Perinatol*. 2017;34(6):541-543.

7. Pariente G, Leibson T, Carls A, Adams-Webber T, Ito S, Koren G. Pregnancy-Associated Changes in Pharmacokinetics: A Systematic Review. Chappell LC, ed. *PLoS Med*. 2016;13(11):e1002160.

8. Lynberg MC, Khoury MJ, Lu X, Cocian T. Maternal flu, fever, and the risk of neural tube defects: A population-based case-control study. *Am J Epidemiol*. 1994;140(3):244-255.

9. Werler MM, Louik C, Mitchell AA. Epidemiologic analysis of maternal factors and amniotic band defects. *Birth Defects Res Part A - Clin Mol Teratol*. 2003;67(1):68-72.

10. Snijder CA, Kortenkamp A, Steegers EAP, et al. Intrauterine exposure to mild analgesics during pregnancy and the occurrence of cryptorchidism and hypospadia in the offspring: The Generation R Study. *Hum Reprod*. 2012;27(4):1191-1201.

11. Lind JN, Tinker SC, Broussard CS, et al. Maternal medication and herbal use and risk for hypospadias: Data from the National Birth Defects Prevention Study, 1997-2007. *Pharmacoepidemiol Drug Saf*. 2013;22(7):783-793.

12. Interrante JD, Ailes EC, Lind JN, et al. Risk comparison for prenatal use of analgesics and selected birth defects, National Birth Defects Prevention Study 1997–2011. *Ann Epidemiol*. 2017;27(10):645-653.e2.

13. Philippat C, Gorgis-Allemand L, Chevrier C, et al. Analgesics during pregnancy and undescended testis. *Epidemiology*. 2011;22(5):747-749.

14. Hernandez RK, Werler MM, Romitti P, Sun L, Anderka M. Nonsteroidal antiinflammatory drug use among women and the risk of birth defects. In: *American Journal of Obstetrics and Gynecology*. Vol 206. Mosby Inc.; 2012:228.e1-228.e8.

15. Cassina M, De Santis M, Cesari E, et al. First trimester diclofenac exposure and pregnancy outcome. *Reprod Toxicol*. 2010;30(3):401-404.

16. Padberg S, Tissen-Diabaté T, Dathe K, et al. Safety of diclofenac use during early pregnancy: A prospective observational cohort study. *Reprod Toxicol*.

2018;77:122-129.

17. van Gelder MMHJ, Roeleveld N, Nordeng H. Exposure to non-steroidal anti-inflammatory drugs during pregnancy and the risk of selected birth defects: A prospective cohort study. *PLoS One*. 2011;6(7).

18. Dathe K, Fietz AK, Pritchard LW, et al. No evidence of adverse pregnancy outcome after exposure to ibuprofen in the first trimester – Evaluation of the national Embryotox cohort. *Reprod Toxicol*. 2018;79:32-38.

19. McElhatton PR, Sullivan FM, Volans GN. Paracetamol overdose in pregnancy analysis of the outcomes of 300 cases referred to the teratology information service. *Reprod Toxicol*. 1997;11(1):85-94.

20. Kozer E, Costei AM, Boskovic R, Nulman I, Nikfar S, Koren G. Effects of aspirin consumption during pregnancy on pregnancy outcomes: Meta-analysis. *Birth Defects Res Part B - Dev Reprod Toxicol*. 2003;68(1):70-84.

21. Ayorinde AA, Wilde K, Lemon J, Campbell D, Bhattacharya S. Data resource profile: The Aberdeen Maternity and Neonatal Databank (AMND). *Int J Epidemiol*. 2016;45(2):389-394.

22. Campbell D, Hall M, Lemon J, Carr-Hill R, Pritchard C, Samphier M. Clinical birthweight standards for a total population in the 1980s. *BJOG An Int J Obstet Gynaecol*. 1993;100(5):436-445.

23. Textor J, van der Zander B, Gilthorpe MS, Liśkiewicz M, Ellison GT. Robust causal inference using directed acyclic graphs: The R package “dagitty.” *Int J Epidemiol*. 2016;45(6):1887-1894.

24. Rebordosa C, Kogevinas M, Bech BH, Sørensen HT, Olsen J. Use of

acetaminophen during pregnancy and risk of adverse pregnancy outcomes. *Int J Epidemiol*. 2009;38(3):706-714.

25. Nielsen GL, Sørensen HT, Larsen H, Pedersen L. Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: Population based observational study and case-control study. *Br Med J*. 2001;322(7281):266-270.

26. Czeizel AE, Dudá I, Puhó E. Short-term paracetamol therapy during pregnancy and a lower rate of preterm birth. *Paediatr Perinat Epidemiol*. 2005;19(2):106-111.

27. Li Z, Ren A, Liu J, et al. Maternal flu or fever, medication use, and neural tube defects: A population-based case-control study in northern China. *Birth Defects Res Part A - Clin Mol Teratol*. 2007;79(4):295-300.

28. Pastore LM, Hertz-Picciotto I, Beaumont JJ. Risk of stillbirth from medications, illnesses and medical procedures. *Paediatr Perinat Epidemiol*. 1999;13(4):421-430.

29. Kristensen DM, Hass U, Lesn L, et al. Intrauterine exposure to mild analgesics is a risk factor for development of male reproductive disorders in human and rat. *Hum Reprod*. 2011;26(1):235-244.

30. Jensen MS, Rebordosa C, Thulstrup AM, et al. Maternal use of acetaminophen, ibuprofen, and acetylsalicylic acid during pregnancy and risk of cryptorchidism. *Epidemiology*. 2010;21(6):779-785.

31. Correy JF, Newman NM, Collins JA, Burrows EA, Burrows RF, Curran JT. Use of prescription drugs in the first trimester and congenital malformations. *Aust N*

Z J Obs Gynaecol. 1991;31(4):340-344.

32. Lind DV, Main KM, Kyhl HB, et al. Maternal use of mild analgesics during pregnancy associated with reduced anogenital distance in sons: A cohort study of 1027 mother-child pairs. *Hum Reprod*. 2017;32(1):223-231.

33. Werler MM, Mitchell AA, Shapiro S. First trimester maternal medication use in relation to gastroschisis. *Teratology*. 1992;45(4):361-367.

34. Torfs CP, Katz EA, Bateson TF, Lam PK, Curry CJR. Maternal medications and environmental exposures as risk factors for gastroschisis. *Teratology*. 1996;54(2):84-92.

35. M. Werler M, Sheehan JE, Mitchell AA. Maternal medication use and risks of gastroschisis and small intestinal atresia. *Am J Epidemiol*. 2002;155(1):26-31.

36. Kozer E, Nikfar S, Costei A, Boskovic R, Nulman I, Koren G. Aspirin consumption during the first trimester of pregnancy and congenital anomalies: A meta-analysis. *Am J Obstet Gynecol*. 2002;187(6):1623-1630.

37. Slone D, Heinonen OP, Kaufman DW, Siskind V, Monson RR, Shapiro S. ASPIRIN AND CONGENITAL MALFORMATIONS. *Lancet*. 1976;307(7974):1373-1375.

38. Shaw GM, Todoroff K, Velie EM, Lammer EJ. Maternal illness, including fever, and medication use as risk factors for neural tube defects. *Teratology*. 1998;57(1):1-7.

39. Mosley II JF, Smith LL, Dezan MD. An overview of upcoming changes in pregnancy and lactation labeling information. *Pharm Pract (Granada)*. 2015;13(2):605.

40. SMFM (Society for Maternal-Fetal Medicine Publications Committee). Prenatal acetaminophen use and outcomes in children. *Am J Obstet Gynecol*. 2017;216(3):B14-B15.

41. Bisson DL, Newell SD, Laxton C. Antenatal and Postnatal Analgesia: Scientific Impact Paper No. 59. *BJOG An Int J Obstet Gynaecol*. 2018;(59).

42. RCOG. RCOG review clarifies pain relief options for women during pregnancy and breastfeeding. https://www.rcog.org.uk/en/news/new-rcog-review-clarifies-pain-relief-options-for-women-during-pregnancy-and-breastfeeding/. Published 2018.

43. Sarganas G, Buttery AK, Zhuang W, et al. Prevalence, trends, patterns and associations of analgesic use in Germany. *BMC Pharmacol Toxicol*. 2015;16(1).

44. Hider-Mlynarz K, Cavalié P, Maison P. Trends in analgesic consumption in France over the last 10 years and comparison of patterns across Europe. *Br J Clin Pharmacol*. 2018;84(6):1324-1334.

Table 1. Comparison of baseline characteristics between exposed (use of analgesics) and unexposed (no analgesic use) groups of pregnancies (P values <0.05 shown in bold).

Baseline Characteristics	No analgesic (n=107,143) n (%)	At least one analgesic (n=43,998) n (%)	P value†	Paracetamol (n=24,099) n (%)	P value†	Ibuprofen/ Aspirin/ Naproxen (n=762) n (%)	P value†	No analgesic 2005-2015 (n=20,544) n (%)	Diclofenac 2005-2015 (n=10,291) n (%)	P value‡
Year of delivery										
1985-1994	50,152 (46.8)	5,737 (13.0)	**<0.001**	5,390 (22.4)	**<0.001**	213 (28.0)	**<0.001**	n/a	n/a	**<0.001**
1995-2004	36,447 (34.0)	7,263 (16.5)		6,571 (27.3)		321 (42.1)		n/a	n/a	
2005-2015 / 2005-2009 *	20,544 (19.2)	30,998 (70.5)		12,138 (50.4)		228 (29.9)		11,105 (54.1)	4,021 (39.1)	
2010-2015 *	n/a	n/a		n/a		n/a		9,439 (45.9)	6,270 (60.9)	
Maternal age at delivery										
Younger than 20	9,236 (8.6)	3,834 (8.7)	**<0.001**	2,936 (12.2)	**<0.001**	34 (4.5)	**<0.001**	1,286 (6.3)	311 (3.0)	**<0.001**
20-25	24,249 (22.6)	8,700 (19.8)		5,932 (24.6)		113 (14.8)		3,436 (16.7)	1,152 (11.2)	
26-35	63,499 (59.3)	25,367 (57.7)		12,896 (53.5)		464 (60.9)		12,664 (61.1)	6,628 (64.4)	
Older than 35	10,159 (9.5)	6,097 (13.9)		2,335 (9.7)		151 (19.8)		3,158 (15.4)	2,200 (21.4)	
Previous Parity										
Nulliparity (0)	48,684 (45.4)	23,353 (53.1)	**<0.001**	12,510 (51.9)	**<0.001**	300 (39.4)	**0.004**	8,336 (40.6)	5,004 (48.6)	<**0.001**
Multiparity (1-11)	58,457 (54.6)	20,639 (46.9)		11,587 (48.1)		462 (60.6)		12,206 (59.4)	5,284 (51.4)	
Missing	2 (<0.1)**§**	6 (<0.1)**§**		2 (<0.1)**§**		0 (0.0)**§**		2 (<0.1)**§**	3 (<0.1)**§**	
Maternal BMI										
Underweight (<18.5)	1,998 (2.4)	869 (2.2)	**<0.001**	545 (2.6)	**<0.001**	10 (1.5)	**0.007**	492 (2.7)	174 (1.9)	**<0.001**
Normal weight (18.5-24.9)	50,127 (60.8)	18,958 (48.8)		10,486 (50.5)		361 (55.)		10,239 (55.2)	4,671 (50.0)	
Overweight (25.0-29.9)	20,500 (24.9)	10,960 (28.2)		5,733 (27.6)		192 (29.5)		4,930 (26.6)	2,630 (28.1)	
Obese (≤ 30.0)	9,773 (11.9)	8,046 (20.7)		3,995 (19.2)		88 (13.5)		2,881 (15.5)	1,871 (20.0)	
Missing data	24,745 (23.1)**§**	5,165 (11.7)**§**		3,340 (13.9)**§**		111 (14.6)**§**		2,002 (9.7)**§**	945 (9.2)**§**	

Gestation weeks at earliest antenatal visit										
1st Trimester	69,896 (65.4)	36,789 (83.7)	**<0.001**	19,075 (79.2)	**<0.001**	569 (75.0)	**<0.001**	18,155 (88.4)	9,185 (89.4)	**0.036**
2nd Trimester	29,269 (27.4)	5,791 (13.2)		4,117 (17.1)		166 (21.9)		1,770 (8.6)	829 (8.1)	
3rd Trimester	7,741 (7.2)	1,376 (3.1)		890 (3.7)		24 (3.2)		605 (2.9)	264 (2.6)	
Missing	237 (0.2)**§**	42 (0.1)**§**		17 (0.1)**§**		3 (0.4)**§**		14 (0.1)**§**	13 (0.1)**§**	
Maternal smoking Status										
Unknown	6,505 (6.1)**§**	819 (1.9)**§**	**<0.001**	500 (2.1)**§**	**<0.001**	32 (4.2)**§**	0.132	448 (2.2)**§**	155 (1.5)**§**	**<0.001**
Ex-smoker	5,952 (5.6)	3,363 (7.6)		1,923 (8.1)		35 (4.8)		1,427 (7.1)	660 (6.5)	
Non-smoker	70,319 (69.9)	31,421 (72.8)		15,755 (66.8)		534 (73.2)		15,525 (77.3)	8,368 (82.6)	
Smoker	24,367 (24.2)	8,395 (19.4)		5,921 (25.1)		161 (22.)		3,144 (15.6)	1,108 (10.9)	
Maternal SIMD Decile										
Least Deprived (7-10)	65,227 (61.8)	25,192 (57.9)	**<0.001**	12,807 (53.8)	**<0.001**	501 (66.3)	**0.012**	12,806 (62.9)	6,714 (66.1)	**<0.001**
Most Deprived (1-6)	40,321 (38.2)	18,289 (42.1)		11,017 (46.2)		255 (33.7)		7,564 (37.1)	3,442 (33.9)	
Missing	1,595 (1.5)**§**	517 (1.2)**§**		275 (1.1)**§**		6 (0.8)**§**		174 (0.8)**§**	135 (1.3)**§**	
Maternal hypertensive disorders										
None	91,276 (85.2)	35,529 (80.8)	**<0.001**	18,635 (77.3)	<**0.001**	636 (83.5)	**0.001**	18,851 (91.8)	9,273 (90.1)	**<0.001**
Gestational Hypertension	13,029 (12.2)	5,501 (12.5)		3,584 (14.9)		88 (11.5)		1,165 (5.7)	690 (6.7)	
Preeclampsia	2,780 (2.6)	2,941 (6.7)		1,861 (7.7)		38 (5.0)		523 (2.5)	324 (3.1)	
Eclampsia	58 (0.1)	27 (0.1)		19 (0.1)		0 (0.0)		5 (<0.1)	4 (<0.1)	
Maternal antepartum haemorrhage										
No haemorrhage	97,527 (91.0)	37,673 (85.6)	**<0.001**	20,306 (84.3)	**<0.001**	684 (89.8)	0.434	18,549 (90.3)	9,244 (89.8)	<0.001
Abruption	697 (0.7)	468 (1.1)		221 (0.9)		8 (1.0)		103 (0.5)	106 (1.0)	
Placenta previa	308 (0.3)	368 (0.8)		152 (0.6)		2 (0.3)		23 (0.1)	114 (1.1)	
Unspecified	8,611 (8.0)	5,489 (12.5)		3,420 (14.2)		68 (8.9)		1,869 (9.1)	827 (8.0)	
Type of labour										
Elective Caesarean Section	5,967 (5.6)	6,925 (15.7)	**<0.001**	1,384 (5.7)	<**0.001**	67 (8.8)	**<0.001**	616 (3.0)	3,843 (37.3)	**<0.001**
Induced	24,120 (22.5)	16,276 (37.0)		10,067 (41.8)		228 (29.9)		3,895 (19.0)	1,998 (19.4)	
Spontaneous	77,056 (71.9)	20,797 (47.3)		12,648 (52.5)		467 (61.3)		16,033 (78.0)	4,450 (43.2)	

Type of delivery										
Spontaneous vaginal delivery (SVD)	75,027 (70.1)	19,287 (43.8)	**<0.001**	15,983 (66.3)	**<0.001**	496 (65.2)	**0.003**	16,398 (79.8)	1,403 (13.6)	**<0.001**
Instrumental	15,409 (14.4)	8,107 (18.4)		4,043 (16.8)		120 (15.8)		2,546 (12.4)	1,927 (18.7)	
Caesarean Section	15,566 (14.5)	16,351 (37.2)		3,879 (16.1)		141 (18.5)		1,509 (7.3)	6,937 (67.4)	
Other	1,096 (1.0)	247 (0.6)		191 (0.8)		4 (0.5)		89 (0.4)	24 (0.2)	
Missing	45 (<0.1)**§**	6 (<0.1)**§**		3 (<0.1)**§**		1 (0.1)**§**		2 (<0.1)**§**	0 (0.0)**§**	
Analgesia during labour										
No	105,176 (98.2)	36,117 (82.1)	**<0.001**	20,974 (87.0)	**<0.001**	729 (95.7)	**<0.001**	19,915 (96.9)	8,235 (80.0)	**<0.001**
Yes	1,967 (1.8)	7,881 (17.9)		3,125 (13.0)		33 (4.3)		629 (3.1)	2,056 (20.0)	
Baby presentation at delivery										
Occiput anterior	11,571 (10.8)	8,152 (18.6)	**<0.001**	2,636 (11.0)	0.525	68 (8.9)	0.093	1,401 (6.8)	2,967 (28.9)	**<0.001**
Occiput posterior	95,352 (89.2)	35,745 (81.4)		21,409 (89.0)		694 (91.1)		19,100 (93.2)	7,306 (71.1)	
Missing	220 (0.2)**§**	101 (0.2)**§**		54 (0.2)**§**		0 (0.0)**§**		43 (0.2)**§**	18 (0.2)**§**	
Sex of baby										
Female	52,265 (48.8)	21,139 (48.0)	**0.010**	11,739 (48.7)	0.861	367 (48.2)	0.732	10,124 (49.3)	4,907 (47.7)	**0.008**
Male	54,866 (51.2)	22,852 (51.9)		12,354 (51.3)		395 (51.8)		10,417 (50.7)	5,384 (52.3)	
Missing	12 (<0.1)**§**	7 (<0.1)**§**		6 (<0.1)**§**		0 (0.0)**§**		3 (<0.1)**§**	0 (0.0)**§**	

n/a, not applicable; n, number of pregnancies

*****Only applicable to Diclofenac 2005-2015 analysis

†p value in comparison to the first ("No analgesic") column

‡p value in comparison to "No analgesic 2005-2015" control column

§Percentage of missing data on total, not included in the analysis

Table 2. Regression analysis of offspring outcomes between control (no analgesic) and groups exposed to at least one analgesic, only paracetamol, and at least one from ibuprofen, aspirin, naproxen.

Outcomes	No analgesic (n=107,143) n (%)	At least one analgesic (n=43,998) n (%)	Crude OR (CI 95%)	Adjusted OR (95% CI)	Paracetamol (n=24,099) n (%)	Crude OR (95% CI)	Adjusted OR (95% CI)	Ibu/Asp/Napr (n=762) n (%)	Crude OR (95% CI)	Adjusted OR (95% CI)
Gestation at delivery (weeks)										
>=37	100,879 (94.2)	39,838 (90.5)	1.00	1.00	21,589 (89.6)	1.00	1.00	697 (91.5)	1.00	1.00
<37	6,264 (5.8)	4,160 (9.5)	**1.68 (1.61-1.75)**	**1.50 (1.43-1.58)** [a]	2,510 (10.4)	**1.87 (1.78-1.97)**	**1.56 (1.48-1.65)** [a]	65 (8.5)	**1.50 (1.16-1.94)**	**1.42 (1.08-1.86)** [a]
Pregnancy outcome										
Livebirth	105,949 (98.9)	43,407 (98.7)	1.00	1.00	23,704 (98.4)	1.00	1.00	747 (98.0)	1.00	1.00
Stillbirth	803 (0.7)	405 (0.9)	**1.23 (1.09-1.39)**	**1.33 (1.15-1.54)** [a]	275 (1.1)	**1.53 (1.33-1.76)**	**1.52 (1.30-1.77)** [a]	13 (1.7)	**2.30 (1.32-3.99)**	**2.34 (1.29-4.25)** [a]
Neonatal Death	373 (0.3)	182 (0.4)	1.19 (0.99-1.42)	**1.56 (1.27-1.93)** [a]	117 (0.5)	**1.40 (1.14-1.73)**	**1.56 (1.24-1.96)** [a]	2 (0.3)	0.76 (0.19-3.06)	0.93 (0.23-3.74) [a]
Missing	18 (<0.1)	4 (<0.1)	n/a	n/a	3 (<0.1)	n/a	n/a	0 (0.0)	n/a	n/a
Weight of baby (grams)										
NBW	87,966 (82.1)	34,555 (78.6)	1.00	1.00	19,163 (79.5)	1.00	1.00	605 (79.5)	1.00	1.00
LBW	5,910 (5.5)	3,571 (8.1)	**1.54 (1.47-1.61)**	**1.28 (1.20-1.37)** [b]	2,213 (9.2)	**1.72 (1.63-1.81)**	**1.60 (1.51-1.69)** [b]	59 (7.7)	**1.45 (1.11-1.90)**	1.29 (0.91-1.83) [b]
HBW	13,233 (12.4)	5,863 (13.3)	**1.13 (1.09-1.17)**	**1.09 (1.05-1.13)** [b]	2,720 (11.3)	**0.94 (0.90-0.99)**	0.98 (0.93-1.02) [b]	97 (12.7)	1.07 (0.86-1.32)	0.99 (0.80-1.24) [b]
Missing	34 (<0.1)	9 (<0.1)	n/a	n/a	3 (<0.1)	n/a	n/a	1 (0.1)	n/a	n/a
Standardised Birthweight Score										
Mean (SD)	0.001 (0.003)	-0.002 (0.065)	**0.03 (0.02-0.04)**	**0.046 (0.032-0.059)** [c]	0.001 (0.991)	**-0.04 (-0.058- -0.029)**	**-0.014 (-0.029-0.001)** [c]	0.046 (0.038)	**0.045 (-0.029-0.119)**	**0.049 (-0.025-0.123)** [c]
Admitted to neonatal unit										
No	62,378 (58.2)	32,391 (73.6)	1.00	1.00	16,342 (67.8)	1.00	1.00	480 (63.0)	1.00	1.00
Yes	11,011 (10.3)	7,448 (16.9)	**1.30 (1.26-1.35)**	**1.57 (1.51-1.64)** [b]	3,956 (16.4)	**1.37 (1.32-1.43)**	**1.45 (1.38-1.53)** [b]	117 (15.4)	**1.38 (1.13-1.69)**	**1.54 (1.22-1.94)** [b]
Missing	33,754 (31.5)	4,159 (9.5)	n/a	n/a	3,801 (15.8)	n/a	n/a	762 (21.7)	n/a	n/a
APGAR score at 1 min										
Normal	92,217 (86.1)	38,224 (86.9)	1.00	1.00	20,593 (85.5)	1.00	1.00	659 (86.5)	1.00	1.00
<7	14,335 (13.4)	5,674 (12.9)	**0.96 (0.92-0.99)**	**1.18 (1.13-1.23)** [d]	3,437(14.3)	**1.07 (1.03-1.12)**	**1.23 (1.18-1.28)** [d]	101 (13.3)	0.99 (0.80-1.22)	1.07 (0.86-1.32) [d]
Missing	591 (0.6)	100 (0.2)		n/a	69 (0.3)	n/a	n/a	2 (0.3)	n/a	n/a
APGAR score at 5 min										
Normal	104,292 (97.3)	42,730 (97.1)	1.00	1.00	23,334 (96.8)	1.00	1.00	738 (96.9)	1.00	1.00
<7	2,216 (2.1)	1,163 (2.6)	**1.28 (1.19-1.38)**	**1.48 (1.35-1.62)** [d]	690 (2.9)	**1.39 (1.28-1.52)**	**1.53 (1.40-1.68)** [d]	21 (2.8)	1.34 (0.87-2.07)	1.52 (0.97-2.36) [d]
Missing	635 (0.6)	105 (0.2)	n/a	n/a	75 (0.3)	n/a	n/a	3 (0.4)	n/a	n/a
Cryptorchidism (only males included)										
No	54,509 (99.3)	22,616 (99.0)	1.00	1.00	12,247 (99.1)	1.00	1.00	394 (99.4)	1.00	1.00
Yes	357 (0.7)	236 (1.0)	**1.59 (1.35-1.88)**	0.92 (0.77-1.11) [b]	107 (0.9)	**1.33 (1.07-1.66)**	0.87 (0.69-1.09) [b]	1 (0.3)	0.39 (0.05-2.77)	0.28 (0.04-1.98) [b]
Neural Tube Defects										

No	107,093 (99.9)	43,928 (99.8)	1.00	1.00	24,077 (99.9)	1.00	1.00	762 (100)	1.00	1.00
Yes	50 (0.1)	70 (0.2)	**3.41 (2.37-4.91)**	**1.64 (1.08-2.47)** [b]	22 (0.1)	**1.96 (1.19-3.23)**	1.21 (0.71-2.06) [b]	0 (0.0)	n/a	n/a
Amniotic Band Defects										
No	107,053 (99.9)	43,936 (99.9)	1.00	1.00	24,070 (99.9)	1.00	1.00	760 (99.7)	1.00	1.00
Yes	90 (0.1)	62 (0.1)	**1.68 (1.21-2.32)**	1.02 (0.71-1.47) [b]	29 (0.1)	1.43 (0.94-2.18)	0.98 (0.63-1.52) [b]	2 (0.3)	3.13 (0.77-12.73)	2.29 (0.56-9.37) [b]
Hypospadias (only males included)										
No	54,607 (99.5)	22,600 (98.9)	1.00	1.00	12,258 (99.2)	1.00	1.00	390 (98.7)	1.00	1.00
Yes	259 (0.3)	252 (1.1)	**2.35 (1.98-2.80)**	**1.27 (1.05-1.54)** [b]	96 (0.8)	**1.65 (1.31-2.09)**	1.07 (0.84-1.37) [b]	5 (1.3)	**2.70 (1.11-6.59)**	1.91 (0.78-4.68) [b]
Gastroschisis										
No	107,120 (99.9)	43,979 (99.9)	1.00	1.00	24,089 (99.9)	1.00	1.00	762(100)	1.00	1.00
Yes	23 (0.1)	19 (0.1)	**2.01 (1.10-3.70)**	1.10 (0.56-2.20) [b]	10 (0.1)	1.93 (0.92-4.06)	0.99 (0.45-2.21) [b]	0 (0.0)	n/a	n/a
At least one outcome*										
No	106,367 (99.3%)	43,363 (98.6%)	1.00	1.00	23,835 (98.9%)	1.00	1.00	754 (99.0%)	1.00	1.00
Yes	776 (0.7%)	635 (1.4%)	**2.01 (1.81-2.23)**	1.12 (0.99-1.26) [b]	264 (1.1%)	**1.52 (1.32-1.75)**	0.97 (0.84-1.13) [b]	8 (1.0%)	1.45 (0.72-2.93)	1.11 (0.55-2.23) [b]

n/a, not applicable; n, number of pregnancies

[a] Adjusted for year of delivery, maternal age at delivery, SIMD, first gestational booking, maternal hypertensive disorders, maternal antepartum haemorrhage

[b] Adjusted for year of delivery, maternal age at delivery, SIMD, first gestational booking, gestation at delivery

[c] Adjusted for year of delivery, maternal age at delivery, SIMD, first gestational booking

[d] Adjusted for year of delivery, maternal age at delivery, SIMD, first gestational booking, type of delivery

*Including cryptorchidism, neural tube defects, amniotic band defects, hypospadias, gastroschisis

Table 3. Sub-group regression analysis between control pregnancies and exposed to diclofenac.

Outcomes	No analgesic (n=20,544) n (%)	Diclofenac 2005-2015 (n=10,291) n (%)	Crude OR (CI 95%)	Adjusted OR (CI 95%)
Gestation at delivery (weeks)				
>=37	19,407 (94.5%)	9,640 (93.7%)	1.00	1.00
<37	1,137 (5.5%)	651 (6.3%)	**1.15 (1.04, 1.27)**	1.10 (0.99, 1.22) [a]
Pregnancy outcome				
Livebirth	20,393 (99.3%)	10,227 (99.4%)	1.00	1.00
Stillbirth	116 (0.5%)	39 (0.4%)	**0.67 (0.47, 0.96)**	**0.59 (0.41, 0.87)** [a]
Neonatal Death	35 (0.2%)	25 (0.2%)	1.42 (0.85, 2.38)	1.26 (0.73, 2.15) [a]
Weight of baby (grams)				
NBW	16,869 (82.1%)	8,116 (78.9%)	1.00	1.00
LBW	965 (4.7%)	572 (5.6%)	**1.23 (1.11, 1.37)**	**1.22 (1.07, 1.40)** [b]
HBW	2,707 (13.2%)	1,600 (15.5%)	**1.23 (1.15, 1.31)**	**1.21 (1.13, 1.29)** [b]
Missing	3 (0.0%)	3 (0.0%)		
Standardised Birthweight Score				
	-0.039 (0.959)	0.132 (1.036)	**0.171 (0.145, 0.197)**	**0.167 (0.141, 0.193)** [c]
Admitted to neonatal unit				
No	18,224 (88.7%)	8,747 (85.0%)	1.00	1.00
Yes	2,175 (10.6%)	1,492 (14.5%)	**1.43 (1.33, 1.53)**	**1.46 (1.35, 1.58)** [b]
Missing	145 (0.7%)	52 (0.5%)		
APGAR score at 1 min				
Normal	18,709 (91.1%)	9,350 (90.9%)	1.00	1.00
<7	1,658 (8.1%)	924 (9.0%)	**1.12 (1.03, 1.21)**	0.93 (0.83, 1.04) [d]
Missing	177 (0.9%)	17 (0.2%)		
APGAR score at 5 min				
Normal	20,065 (97.7%)	10,096 (98.1%)	1.00	1.00
<7	302 (1.5%)	177 (1.7%)	0.86 (0.71, 1.04)	0.94 (0.72, 1.23) [d]
Missing	177 (0.9%)	18 (0.2%)		
Cryptorchidism (only males included)				
No	10,284 (98.7%)	5,314 (98.7%)	1.00	1.00
Yes	133 (1.3%)	70 (1.3%)	1.02 (0.76, 1.36)	1.05 (0.78, 1.42) [b]
Neural Tube Defects				
No	20,527 (99.9%)	10,263 (99.7%)	1.00	1.00
Yes	17 (0.1%)	28 (0.3%)	**3.29 (1.80, 6.02)**	**3.62 (1.95, 6.74)** [b]
Amniotic Band Defects				
No	20,514 (99.9%)	10,277 (99.9%)	1.00	1.00
Yes	30 (0.1%)	14 (0.1%)	0.93 (0.49, 1.76)	0.81 (0.41, 1.58) [b]
Hypospadias (only males included)				
No	10,317 (99.0%)	5,308 (98.6%)	1.00	1.00
Yes	100 (1.0%)	76 (1.4%)	**1.48 (1.09, 1.99)**	**1.49 (1.09, 2.03)** [b]
Gastroschisis				
No	20,538 (99.9%)	10,284 (99.9%)	1.00	1.00
Yes	6 (0.1%)	7 (0.1%)	2.33 (0.78, 6.94)	2.93 (0.97, 8.88) [b]
At least one outcome*				
No	20,258 (98.6%)	10,097 (98.1%)	1.00	1.00
Yes	286 (1.4%)	194 (1.9%)	**1.36 (1.13, 1.64)**	**1.38 (1.15, 1.67)** [b]

n/a, not applicable; n, number of pregnancies

[a] Adjusted for year of delivery, maternal age at delivery, SIMD, first gestational booking, maternal hypertensive disorders, maternal antepartum haemorrhage

[b] Adjusted for year of delivery, maternal age at delivery, SIMD, first gestational booking, gestation at delivery

[c] Adjusted for year of delivery, maternal age at delivery, SIMD, first gestational booking

[d] Adjusted for year of delivery, maternal age at delivery, SIMD, first gestational booking, type of delivery

*Including cryptorchidism, neural tube defects, amniotic band defects, hypospadias, gastroschisis



Figure 1. Flowchart of cohort selection and sub-group analyses. n=number of pregnancies in each analysis,*98.3% of pregnancies using only diclofenac were during 2005-2015, therefore analysis was performed only on data from that decade to rule out any temporal effect



Figure 2. Prevalence of use during pregnancy for each analgesic sub-group over our 30-year study period. In 2005 there was a change in legislation making diclofenac available without prescription



Figure S1. Directed acyclic graph (DAG) of exposure to outcome path and relevant measured and unmeasured biasing factors in our analysis